Advanced search
Publication Cover
Future Science OA Volume 1, 2015 - Issue 4
Submit an article Journal homepage
1,521
Views
10
CrossRef citations to date
0
Altmetric
Case Report

Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor

Thomas Grellety1 Department of Medical Oncology, Institut Bergonié, Bordeaux, FranceView further author information
,
Michèle Kind2 Department of Radiology, Institut Bergonié, Bordeaux, FranceView further author information
,
Jean-Michel Coindre3 Department of Pathology, Institut Bergonié, Bordeaux, FranceView further author information
&
Antoine Italiano1 Department of Medical Oncology, Institut Bergonié, Bordeaux, FranceCorrespondence[email protected]
View further author information
Article: FSO33 | Published online: 24 Jun 2015

References

  • Cassier PA , DucimetièreF, LurkinAet al. A prospective epidemiological study of new incident GISTs during two consecutive years in Rhone Alpes region: incidence and molecular distribution of GIST in a European region. Br. J. Cancer103(2), 165–170 (2010).
  • Tran T , DavilaJA, El-SeragHB. The epidemiology of malignant gastrointestinal stromal tumors: an ana-lysis of 1,458 cases from 1992 to 2000. Am. J. Gastroenterol.100(1), 162–168 (2005).
  • Corless CL , BarnettCM, HeinrichMC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat. Rev. Cancer11(12), 865–878 (2011).
  • Blanke CD , DemetriGD, von MehrenMet al. Long-term results from a randomized Phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol.26(4), 620–625 (2008).
  • Wozniak A , RutkowskiP, PiskorzAet al. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish clinical GIST registry experience. Ann. Oncol.23(2), 353–360 (2012).
  • Corless CL , SchroederA, GriffithDet al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol.23(23), 5357–5364 (2005).
  • Prenen H , CoolsJ, MentensNet al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin. Cancer Res.12(8), 2622–2627 (2006).
  • George S , WangQ, HeinrichMCet al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter Phase II trial. J. Clin. Oncol.30(19), 2401–2407 (2012).
  • Demetri GD , ReichardtP, KangYKet al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet381(9863), 295–302 (2013).
  • Joensuu H , RutkowskiP, NishidaTet al. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. J. Clin. Oncol.33, 634–642 (2015).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.